A Decade on SIX Swiss Exchange: How an IPO Expedited Molecular Partners’ Growth Journey

In this milestone story, SIX Swiss Exchange looks at how going public over a decade ago has helped leading Swiss biotech company Molecular Partners to thrive.

A Decade on SIX Swiss Exchange: How an IPO Expedited Molecular Partners’ Growth Journey
Published at
Medium
News

More than a decade has elapsed since Molecular Partners’ IPO on the SIX Swiss Exchange. Patrick Amstutz, CEO at Molecular Partners, provides his unique insights on why the listing was so instrumental to the company’s growth and development.

The Challenge: Molecular Partners wanted to boost its visibility, attract capital and drive international growth.

The solution: Listing on SIX Swiss Exchange enabled Molecular Partners to tap both local investors who were well-versed in biotech and a deep pool of global investors.

The Result: This funding has been an accelerant for innovation, allowing Molecular Partners to push through with clinical development. The added financial cushion has also helped the company withstand recent market shocks. 

 

Accelerating Growth Through Listing: How Molecular Partners’ IPO Put It on the Path to Success

Molecular Partners, a leading Swiss biotech company, went public on SIX Swiss Exchange just over ten years ago. On a dedicated page, the Exchange reflects on how the IPO has facilitated Molecular Partners’ exciting growth story.

Read the full story and watch the entire interview with Patrick Amstutz